DOCSLIB.ORG

MFS® Research International Fund (Class R6 Shares) Second Quarter 2021 Investment Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
MFS® Research International Fund (Class R6 Shares) Second Quarter 2021 Investment Report MFS® Research International Fund (Class R6 Shares) Second quarter 2021 investment report NOT FDIC INSURED MAY LOSE VALUE NOT A DEPOSIT Before investing, consider the fund's investment objectives, risks, charges, and expenses. For a prospectus, or summary prospectus, containing this and other information, contact MFS or view online at mfs.com. Please read it carefully. ©2021 MFS Fund Distributors, Inc., 111 Huntington Avenue, Boston, MA 02199. FOR DEALER AND INSTITUTIONAL USE ONLY. Not to be shown, quoted, or distributed to the public. PRPEQ-RIF-30-Jun-21 34135 Table of Contents Contents Page Fund Risks 1 Disciplined Investment Approach 2 Market Overview 3 Executive Summary 4 Performance 5 Attribution 6 Significant Transactions 10 Portfolio Positioning 11 Characteristics 13 Portfolio Outlook 14 Portfolio Holdings 18 Additional Disclosures 21 Country and region information contained in this report is based upon MFS classification methodology which may differ from the methodology used by individual benchmark providers. Performance and attribution results are for the fund or share class depicted and do not reflect the impact of your contributions and withdrawals. Your personal performance results may differ. Portfolio characteristics are based on equivalent exposure, which measures how a portfolio's value would change due to price changes in an asset held either directly or, in the case of a derivative contract, indirectly. The market value of the holding may differ. 0 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund PRPEQ-RIF-30-Jun-21 Fund Risks The fund may not achieve its objective and/or you could lose money on your investment in the fund. Stock: Stock markets and investments in individual stocks are volatile and can decline significantly in response to or investor perception of, issuer, market, economic, industry, political, regulatory, geopolitical, environmental, public health, and other conditions. International: Investments in foreign markets can involve greater risk and volatility than U.S. investments because of adverse market, currency, economic, industry, political, regulatory, geopolitical, or other conditions. Please see the prospectus for further information on these and other risk considerations. 1 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund 1 PRPEQ-RIF-30-Jun-21 Disciplined Investment Approach Investment objective Seekscapitalappreciation Goal OutperformtheMSCIEAFEIndex(netdiv)over full market cycles Webelievebottom-upanalysis offers thebest opportunitytotry to identifyhigh-quality companies (generally definedas sustainable, Philosophy durable franchises, significant freecashflow, solid balance sheetsand strong management teams)with above average, sustainable earnings growth potential Analyst-driven decision making process Core, multi-capitalization investment strategyallows flexibility to search Strategy for highest conviction ideas Company specificstockselection, not country specific Generally, hasbeensectorneutral relative toMSCIEAFEIndex 2 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund 2 PRPEQ-RIF-30-Jun-21 Market Overview Region performance (%) (USD) as of 30-Jun-21 Sector performance (%) (USD) as of 30-Jun-21 2Q 2021 1 Year 2Q 2021 1 Year 45.0 45.8 41.2 42.4 41.9 40.9 38.9 36.2 34.2 31.3 24.8 23.2 21.5 17.5 10.0 8.8 7.8 12.2 6.0 5.0 4.8 9.4 9.0 7.5 6.2 4.3 3.8 1.0 -0.3 -1.0 UK Japan Energy Canada Markets Emerging Emerging Health Care Health Technology Capital Goods Capital Telecom/CATV Europe ex UK ex Europe UnitedStates Pacific ex Japanex Pacific Financial Services Financial Consumer Staples Consumer Consumer Cyclicals Consumer Source: FactSet. Region performance based on MSCI regional/country indexes. Source: FactSet. Sector performance based on Global Research sector classification. The analysis of MSCI EAFE Index constituents are broken out by MFS defined sectors. Market review as of 30-Jun-21 The global equity market rally continued in Q2 of 2021, helped by the The growing debate around inflation, even if transitory, is likely to increase further reopening of economies and expanding vaccinations despite the volatility in the market as short-term investors try to switchfrom growthto spread of COVID variants around the world. value and vice versa based on near-term news. Investors’ focus has begun to shift from the post-pandemic recovery to longer-term earnings growth. 3 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund 3 PRPEQ-RIF-30-Jun-21 Executive Summary Performance results (%) R6 shares at NAV (USD) as of 30-Jun-21 Sector weights (%) as of 30-Jun-21 Portfolio Benchmark^^ Portfolio Benchmark^ Top overweights Technology 13.5 13.4 Top underweights Energy 6.2 6.7 32.35 30.29 Health Care 11.9 12.3 Capital Goods 24.4 24.6 ^^ MSCI EAFE Index The sectors described and the associated portfolio composition are based on MFS' own sector classification methodology which differs from 12.13 industry classification standards, including the standard that is 10.28 11.00 8.27 7.73 8.83 associated with the benchmark composition presented. The variance in 6.28 5.89 5.43 5.17 sector weights between the portfolio and the benchmark would be different if an industry classification standard was used. 10 year 5 year 3 year 1 year YTD 2Q 2021 The MFS Research International Fund outperformed the MSCI EAFE Index in the second quarter of 2021. Performance data shown represent past performance and are no guarantee of future results. Investment return and principal value fluctuate so your shares, when sold, may be worth Contributors Detractors more or less than the original cost; current performance may be lower or higher than quoted. • Technology – Stock selection • Energy – Stock selection For most recent month-end performance, please visit mfs.com. •Individual stocks: • Capital Goods – Stock selection Performance results reflect any applicable expense subsidies and waivers in effect during the - Novo Nordisk •Individual stocks: periods shown. Without such subsidies and waivers the fund's performance results would be less - Kyowa Kirin Co Ltd - Royal Philips Electronics NV favorable. All results assume the reinvestment of dividends and capital gains. - Asml Holding Nv (not held) Shares are available without a sales charge to eligible investors. For periods of less than one-year returns are not annualized. Source for benchmark performance SPAR, FactSet Research Systems Inc. ^ MSCI EAFE (Europe, Australasia, Far East) Index (net div) 4 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund 4 PRPEQ-RIF-30-Jun-21 Performance Results Performance results (%) R6 shares at NAV (USD) as of 30-Jun-21 Excess return vs Period Portfolio (%) Benchmark^ (%) benchmark (%) 3Q 2020 7.57 4.80 2.77 4Q 2020 12.43 16.05 -3.62 1Q 2021 2.18 3.48 -1.30 2Q 2021 5.43 5.17 0.26 2016 -0.75 1.00 -1.75 2017 28.45 25.03 3.42 2018 -13.87 -13.79 -0.08 2019 28.12 22.01 6.11 2020 13.29 7.82 5.47 2021 YTD 7.73 8.83 -1.10 10 year 6.28 5.89 0.39 5 year 12.13 10.28 1.86 3 year 11.00 8.27 2.73 1 year 30.29 32.35 -2.06 Performance data shown represent past performance and are no guarantee of future results. Investment return and principal value fluctuate so your shares, when sold, may be worth more or less than the original cost; current performance may be lower or higher than quoted. For most recent month-end performance, please visit mfs.com. Performance results reflect any applicable expense subsidies and waivers in effect during the periods shown. Without such subsidies and waivers the fund's performance results would be less favorable. All results assume the reinvestment of dividends and capital gains. Shares are available without a sales charge to eligible investors. For periods of less than one-year returns are not annualized. Source for benchmark performance SPAR, FactSet Research Systems Inc. ^ MSCI EAFE (Europe, Australasia, Far East) Index (net div) 5 FOR DEALER AND INSTITUTIONAL USE ONLY. - MFS Research International Fund 5 PRPEQ-RIF-30-Jun-21 Performance Drivers - Sectors Average Relative Relative to MSCI EAFE Index (USD) - second Portfolio Benchmark Sector Stock Currency relative + + = contribution quarter 2021 returns (%) returns (%) allocation1 (%) selection2 (%) effect (%) weighting (%) (%) Contributors Technology -0.2 10.2 6.2 0.0 0.5 0.0 0.5 Consumer Cyclicals -0.1 9.5 7.5 -0.0 0.2 0.0 0.2 Financial Services -0.1 4.6 3.8 -0.0 0.1 0.1 0.2 Health Care -0.3 9.9 9.4 -0.0 0.0 0.0 0.0 Telecom/CATV -0.0 -0.6 -1.0 0.0 0.0 -0.0 0.0 Detractors Energy -0.3 -2.7 1.0 0.0 -0.3 0.0 -0.2 Capital Goods -0.5 3.3 4.3 0.0 -0.3 0.0 -0.2 Consumer Staples 0.0 7.6 9.0 0.0 -0.1 -0.0 -0.1 Cash 1.5 0.0 – -0.1 – 0.0 -0.1 Total 5.6 5.4 -0.0 0.2 0.1 0.3 1 Sector allocation is calculated based upon each security's price in local currency. 2 Stock selection is calculated based upon each security's price in local currency and included interaction effect. Interaction effect is the portion of the portfolio's relative performance attributable to combining allocation decisions with stock selection decisions. This effect measures the relative strength of the manager's convictions. The interaction effect is the weight differential times the return differential. Attribution results are generated by the FactSet application utilizing a methodology that is widely accepted in the investment industry. Results are based upon daily holdings using a buy-and-hold methodology to generate individual security returns and do not include fees or expenses.
Load more

Recommended publications
  • OSB Representative Participant List by Industry
    OSB Representative Participant List by Industry Aerospace • KAWASAKI • VOLVO • CATERPILLAR • ADVANCED COATING • KEDDEG COMPANY • XI'AN AIRCRAFT INDUSTRY • CHINA FAW GROUP TECHNOLOGIES GROUP • KOREAN AIRLINES • CHINA INTERNATIONAL Agriculture • AIRBUS MARINE CONTAINERS • L3 COMMUNICATIONS • AIRCELLE • AGRICOLA FORNACE • CHRYSLER • LOCKHEED MARTIN • ALLIANT TECHSYSTEMS • CARGILL • COMMERCIAL VEHICLE • M7 AEROSPACE GROUP • AVICHINA • E. RITTER & COMPANY • • MESSIER-BUGATTI- CONTINENTAL AIRLINES • BAE SYSTEMS • EXOPLAST DOWTY • CONTINENTAL • BE AEROSPACE • MITSUBISHI HEAVY • JOHN DEERE AUTOMOTIVE INDUSTRIES • • BELL HELICOPTER • MAUI PINEAPPLE CONTINENTAL • NASA COMPANY AUTOMOTIVE SYSTEMS • BOMBARDIER • • NGC INTEGRATED • USDA COOPER-STANDARD • CAE SYSTEMS AUTOMOTIVE Automotive • • CORNING • CESSNA AIRCRAFT NORTHROP GRUMMAN • AGCO • COMPANY • PRECISION CASTPARTS COSMA INDUSTRIAL DO • COBHAM CORP. • ALLIED SPECIALTY BRASIL • VEHICLES • CRP INDUSTRIES • COMAC RAYTHEON • AMSTED INDUSTRIES • • CUMMINS • DANAHER RAYTHEON E-SYSTEMS • ANHUI JIANGHUAI • • DAF TRUCKS • DASSAULT AVIATION RAYTHEON MISSLE AUTOMOBILE SYSTEMS COMPANY • • ARVINMERITOR DAIHATSU MOTOR • EATON • RAYTHEON NCS • • ASHOK LEYLAND DAIMLER • EMBRAER • RAYTHEON RMS • • ATC LOGISTICS & DALPHI METAL ESPANA • EUROPEAN AERONAUTIC • ROLLS-ROYCE DEFENCE AND SPACE ELECTRONICS • DANA HOLDING COMPANY • ROTORCRAFT • AUDI CORPORATION • FINMECCANICA ENTERPRISES • • AUTOZONE DANA INDÚSTRIAS • SAAB • FLIR SYSTEMS • • BAE SYSTEMS DELPHI • SMITH'S DETECTION • FUJI • • BECK/ARNLEY DENSO CORPORATION
    [Show full text]
  • Important Notice the Depository Trust Company
    Important Notice The Depository Trust Company B #: 12945-20 Date: February 10, 2020 To: All Participants Category: Dividends | International From: Global Tax Services Attention: Managing Partner/Officer, Cashier, Dividend Mgr., Tax Mgr. BNY Mellon | ADRs | Qualified Dividends for Tax Year 2019 Subject: Bank of New York Mellon Corporation (“BNYM”), as depositary for these issues listed below has reviewed and determined if they met the criteria for reduced U.S. tax rate as “qualified dividends” for tax year 2019. The Depository Trust Company received the attached correspondence containing Tax Information. If applicable, please consult your tax advisor to ensure proper treatment of these events. Non-Confidential DTCC Public (White) 2019 DIVIDEND CERTIFICATION CUSIP DR Name Country Exchange Qualified 000304105 AAC TECHNOLOGIES HLDGS INC CAYMAN ISLANDS OTC N 000380105 ABCAM PLC UNITED KINGDOM OTC Y 001201102 AGL ENERGY LTD AUSTRALIA OTC Y 001317205 AIA GROUP LTD HONG KONG OTC N 002482107 A2A SPA ITALY OTC Y 003381100 ABERTIS INFRAESTRUCTURAS S A SPAIN OTC Y 003725306 ABOITIZ EQUITY VENTURES INC PHILIPPINES OTC Y 003730108 ABOITIZ PWR CORP PHILIPPINES OTC Y 004563102 ACKERMANS & VAN HAAREN BELGIUM OTC Y 004845202 ACOM CO. JAPAN OTC Y 006754204 ADECCO GROUP AG SWITZERLAND OTC Y 007192107 ADMIRAL GROUP UNITED KINGDOM OTC Y 007627102 AEON CO LTD JAPAN OTC Y 008712200 AIDA ENGR LTD JAPAN OTC Y 009126202 AIR LIQUIDE FRANCE OTC Y 009279100 AIRBUS SE NETHERLANDS OTC Y 009707100 AJINOMOTO INC JAPAN OTC Y 015096209 ALEXANDRIA MINERAL - REG. S EGYPT None N 015393101 ALFA LAVAL AB SWEDEN SWEDEN OTC Y 021090204 ALPS ELEC LTD JAPAN OTC Y 021244207 ALSTOM FRANCE OTC Y 022205108 ALUMINA LTD AUSTRALIA OTC Y 022631204 AMADA HLDGS CO LTD JAPAN OTC Y 023511207 AMER GROUP HOLDING - REG.
    [Show full text]
  • Symrise Has Always Been Creating Exciting Taste and Fragrance Experiences – This Is at the Heart of Our Daily Operations
    Key Figures of the Group 2010 2011 2012 2013 2014 Business Sales € million 1,571.9 1,583.6 1,734.9 1,830.4 2,120.1 EBITDA 1 € million 331.2 315.9 338.9 373.1 464.5 EBITDA margin 1 in % 21.1 20.0 19.5 20.4 21.9 EBIT 1 € million 244.4 234.4 252.6 283.1 337.9 EBIT margin 1 in % 15.5 14.8 14.6 15.5 15.9 Net income 1 € million 133.5 146.5 157.5 172.3 211.6 Balance sheet total (as of December 31) € million 2,059.0 2,120.3 2 2,150.2 2 2,210.4 3,999.8 Capital ratio (as of December 31) in % 40.9 40.9 2 40.9 2 43.0 35.8 Investments (without M & A) € million 70.5 67.3 70.3 70.7 101.3 Net debt (incl. pension provisions and similar obligations) / EBITDA (as of December 31) 1 ratio 2.2 2.4 2 2.4 2 2.0 3.2 Research and development expenses 1 € million 107.9 107.6 113.8 127.0 138.9 Operating cash flow € million 235.1 200.9 219.5 274.8 343.2 Capital Market Shares issued as of balance sheet date millions 118.2 118.2 118.2 118.2 129.8 Share price at end of fiscal year (Xetra® closing price) in € 20.53 20.62 27.12 33.50 50.13 Market capitalization at end of fiscal year € million 2,426.1 2,436.7 3,204.9 3,958.8 6,507.5 Earnings per share 1 in € 1.13 1.24 1.33 1.46 1.69 Dividend per share in € 0.60 0.62 0.65 0.70 0.75 3 Environment Carbon dioxide emissions (Scope 1 and Scope 2) 4, 5 in t 254.44 251.61 240.51 226.00 205.13 Chemical oxygen demand (COD) in wastewater 4, 5 in t 5.96 6.47 5.73 5.68 4.88 Sensitive waste 4, 5 in t 21.97 18.74 16.51 14.99 15.54 Employees Employees (as of December 31) FTE 6 5,288 5,434 5,669 5,959 8,160 Fluctuation rate in % 5.1 5.5 5.3 4.4 4.8 Number of accidents MAQ 7 5.0 3.2 5.3 5.3 4.8 As a result of the combination of the business activities with Diana, only the key financial figures and numbers of employees are presented in the consolidated form.
    [Show full text]
  • Prospectus Dated 26 June 2020 Symrise AG (A Stock Corporation
    Prospectus dated 26 June 2020 Symrise AG (a stock corporation incorporated under the laws of the Federal Republic of Germany, having its corporate domicile in Holzminden, Federal Republic of Germany) € 500,000,000 1.375 per cent. Notes due 2027 Issue Price: 99.320 per cent. Symrise AG (the "Issuer", "Symrise" or "Symrise AG") will issue on 1 July 2020 (the "Issue Date") EUR 500,000,000 1.375 per cent. Notes due 2027 (the "Notes"). Unless previously redeemed in accordance with their conditions of issue, the Notes will be redeemed at par on 1 July 2027. The Notes will bear interest from and including 1 July 2020 to, but excluding, 1 July 2027 at a rate of 1.375 per cent. per annum, payable annually in arrear on 1 July in each year, commencing on 1 July 2021. This prospectus (the "Prospectus") constitutes a prospectus within the meaning of Article 6 of Regulation (EU) 2017/1129 of the European Parliament and the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading, as amended (the "Prospectus Regulation"). This Prospectus will be published in electronic form together with all documents incorporated by reference on the website of the Luxembourg Stock Exchange (www.bourse.lu) and the website of the Issuer (www.symrise.com). This Prospectus has been approved by the Commission de Surveillance du Sector Financier (the "CSSF") in its capacity as competent authority under the Prospectus Regulation. The CSSF only approves this Prospectus as meeting the standards of completeness, comprehensibility and consistency imposed by the Prospectus Regulation.
    [Show full text]
  • Retirement Strategy Fund 2060 Description Plan 3S DCP & JRA
    Retirement Strategy Fund 2060 June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA ACTIVIA PROPERTIES INC REIT 0.0137% 0.0137% AEON REIT INVESTMENT CORP REIT 0.0195% 0.0195% ALEXANDER + BALDWIN INC REIT 0.0118% 0.0118% ALEXANDRIA REAL ESTATE EQUIT REIT USD.01 0.0585% 0.0585% ALLIANCEBERNSTEIN GOVT STIF SSC FUND 64BA AGIS 587 0.0329% 0.0329% ALLIED PROPERTIES REAL ESTAT REIT 0.0219% 0.0219% AMERICAN CAMPUS COMMUNITIES REIT USD.01 0.0277% 0.0277% AMERICAN HOMES 4 RENT A REIT USD.01 0.0396% 0.0396% AMERICOLD REALTY TRUST REIT USD.01 0.0427% 0.0427% ARMADA HOFFLER PROPERTIES IN REIT USD.01 0.0124% 0.0124% AROUNDTOWN SA COMMON STOCK EUR.01 0.0248% 0.0248% ASSURA PLC REIT GBP.1 0.0319% 0.0319% AUSTRALIAN DOLLAR 0.0061% 0.0061% AZRIELI GROUP LTD COMMON STOCK ILS.1 0.0101% 0.0101% BLUEROCK RESIDENTIAL GROWTH REIT USD.01 0.0102% 0.0102% BOSTON PROPERTIES INC REIT USD.01 0.0580% 0.0580% BRAZILIAN REAL 0.0000% 0.0000% BRIXMOR PROPERTY GROUP INC REIT USD.01 0.0418% 0.0418% CA IMMOBILIEN ANLAGEN AG COMMON STOCK 0.0191% 0.0191% CAMDEN PROPERTY TRUST REIT USD.01 0.0394% 0.0394% CANADIAN DOLLAR 0.0005% 0.0005% CAPITALAND COMMERCIAL TRUST REIT 0.0228% 0.0228% CIFI HOLDINGS GROUP CO LTD COMMON STOCK HKD.1 0.0105% 0.0105% CITY DEVELOPMENTS LTD COMMON STOCK 0.0129% 0.0129% CK ASSET HOLDINGS LTD COMMON STOCK HKD1.0 0.0378% 0.0378% COMFORIA RESIDENTIAL REIT IN REIT 0.0328% 0.0328% COUSINS PROPERTIES INC REIT USD1.0 0.0403% 0.0403% CUBESMART REIT USD.01 0.0359% 0.0359% DAIWA OFFICE INVESTMENT
    [Show full text]
  • Symrise AG / Executive Board Contracts with Dr. Heinz-Jürgen Bertram, Hans Holger Gliewe and Bernd Hirsch Extended
    Symrise AG 08.12.2011 – 07:02 Uhr EANS-News: Symrise AG / Executive Board contracts with Dr. Heinz-Jürgen Bertram, Hans Holger Gliewe and Bernd Hirsch extended -------------------------------------------------------------------------------- Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- Board of Directors (Appointments and Changes) Holzminden, December 8, 2011 (euro adhoc) - The Symrise AG Supervisory Board has extended the contract with Chief Executive Officer Dr. Heinz-Jürgen Bertram until the end of 2017. The contracts with Hans Holger Gliewe, Board Member for the Flavor & Nutrition division, and Chief Financial Officer, Bernd Hirsch, were extended until the end of 2015. This step ensures con-tinuity in Symrise´s senior management team. Achim Daub who is responsible for the Scent & Care division is also part of the Board. Dr. Thomas Rabe, Chairman of the Supervisory Board, said: "We are delighted about the contract extensions for Dr. Bertram, Mr. Gliewe and Mr. Hirsch. Together with their colleague Achim Daub, they form an experienced and successful management team that will continue to lead the company with a steady hand and clear perspective. This continuity is a very strong signal to staff, customers and shareholders. Symrise is excellently positioned, both strategically and financially, and has best possible prospects for further profitable growth. The Supervisory Board looks forward to continuing the successful working relationship with the Executive Board over the coming years." Dr. Heinz-Jürgen Bertram has meanwhile over twenty years´ service at Symrise and its predecessor company, Haarmann & Reimer. Mr. Ber-tram, who has a PhD in chemistry, was appointed to the Executive Board in 2006 and became Chief Executive Officer in 2009.
    [Show full text]
  • FCF Valuation Monitor German Small- / Midcap Companies – Q2 2020 AGENDA Executive Summary I
    FCF Valuation Monitor German Small- / Midcap Companies – Q2 2020 AGENDA Executive Summary I. FCF Overview II. Market Overview III. Sector Overview IV. Sector Analysis A p p e n d i x Executive Summary The FCF Valuation FCF Valuation Monitor Recipients Monitor is a standardized report is a comprehensive valuation analysis for the German small / midcap The FCF Valuation Monitor targets the following recipients: on valuations in the market segment and is published by FCF on a quarterly basis German small / ■ Institutional investors ■ Family Offices / High Net- midcap segment and ■ Private equity investors Worth Individuals is a quick reference ■ Venture capital investors ■ Corporates Selection of Companies for investors, ■ Advisors corporates and professionals The selection of companies is primarily based on the regulated market of the Deutsche Börse: Data ■ Large cap DAX 30 companies are excluded All input data is provided by S&P Capital IQ and is not independently More advanced, verified by FCF. Ratio and multiple calculations are driven based on ■ Certain sectors which are dominated by large cap companies detailed and / or the input data available. For additional information and disclaimer, or which are of limited relevance for a small / midcap analysis please refer to the last page customized reports have been excluded (e.g. financials, utilities, automotive are available upon manufacturers and specialty sectors such as biotech and request healthcare services / hospitals) Availability ■ The allocation of companies into a specific sector
    [Show full text]
  • Incoming Letter: QIAGEN N.V
    WACHTELL, LIPTON , ROSEN & KATZ MARTIN LIPTON STEVEN A. COHEN 51 W E S T 52N D S T R E E T DAVID E. SHAPIRO SABASTIAN V. NILES HERBERT M. WACHTELL DEBORAH L. PAUL DAMIAN G. DIDDEN ALISON ZIESKE PREISS THEODORE N. MIRVIS DAVID C. KARP NEW YORK, N.Y. 1 0 0 1 9 - 6 1 5 0 IAN B OC Z K O TIJANA J. DVORNIC EDWARD D. HERLIHY RICHARD K. KIM MATTHEW M. GUEST JENNA E. LEVINE DANIEL A. NEFF JOSHUA R. CAMMAKER TELEPHONE: (212) 403 -1000 DAVID E. KAHAN RYAN A. McLEOD ANDREW R. BROWNSTEIN MARK GORDON DAVID K. LAM ANITHA REDDY MARC WOLINSKY JOSEPH D. LARSON FACSIMILE: (212) 403 -2000 BENJAMIN M. ROTH JOHN L. ROBINSON STEVEN A. ROSENBLUM JEANNEMARIE O’BRIEN JOSHUA A. FELTMAN JOHN R. SOBOLEWSKI JOHN F. SAVARESE WAYNE M. CARLIN GEORGE A. KATZ (1965 -1 9 8 9) ELAINE P. GOLIN STEVEN WINTER SCOTT K. CHARLES STEPHEN R. D iPRIMA JAMES H. FOGELSON (1967 - 1 9 91) EMI L A. KLEINHAUS EMILY D. JOHNSON JODI J. SCHWARTZ NICHOLAS G. DEMMO LEONARD M. ROSEN (1965 - 2 0 14 ) KARESSA L. CAIN JACOB A. KLING ADAM O. EMMERICH IGOR KIRMAN RONALD C. CHEN RAAJ S. NARAYAN RALPH M. LEVENE JONATHAN M. MOSES OF C O UN S EL GORDON S. MOODIE VIKTOR SAPEZHNIKOV RICHARD G. MASON T. EIKO STANGE DONGJU SONG MICHAEL J. SCHOBEL MARTIN J.E. ARMS ERIC S. ROBINSON DAVID M. SILK JOHN F. LYNCH BRADLEY R. WILSON ELINA TETELBAUM MICHAEL H. BYOWITZ PATRICIA A. ROBINSON* ROBIN PANOVKA WILLIAM SAVITT GRAHAM W.
    [Show full text]
  • List of SARS-Cov-2 Diagnostic Test Kits and Equipments Eligible For
    Version 33 2021-09-24 List of SARS-CoV-2 Diagnostic test kits and equipments eligible for procurement according to Board Decision on Additional Support for Country Responses to COVID-19 (GF/B42/EDP11) The following emergency procedures established by WHO and the Regulatory Authorities of the Founding Members of the GHTF have been identified by the QA Team and will be used to determine eligibility for procurement of COVID-19 diagnostics. The product, to be considered as eligible for procurement with GF resources, shall be listed in one of the below mentioned lists: - WHO Prequalification decisions made as per the Emergency Use Listing (EUL) procedure opened to candidate in vitro diagnostics (IVDs) to detect SARS-CoV-2; - The United States Food and Drug Administration’s (USFDA) general recommendations and procedures applicable to the authorization of the emergency use of certain medical products under sections 564, 564A, and 564B of the Federal Food, Drug, and Cosmetic Act; - The decisions taken based on the Canada’s Minister of Health interim order (IO) to expedite the review of these medical devices, including test kits used to diagnose COVID-19; - The COVID-19 diagnostic tests approved by the Therapeutic Goods Administration (TGA) for inclusion on the Australian Register of Therapeutic Goods (ARTG) on the basis of the Expedited TGA assessment - The COVID-19 diagnostic tests approved by the Ministry of Health, Labour and Welfare after March 2020 with prior scientific review by the PMDA - The COVID-19 diagnostic tests listed on the French
    [Show full text]
  • Euro Stoxx® Multi Premia Index
    EURO STOXX® MULTI PREMIA INDEX Components1 Company Supersector Country Weight (%) SARTORIUS STEDIM BIOTECH Health Care France 1.59 IMCD Chemicals Netherlands 1.25 VOPAK Industrial Goods & Services Netherlands 1.15 BIOMERIEUX Health Care France 1.04 REMY COINTREAU Food, Beverage & Tobacco France 1.03 EURONEXT Financial Services France 1.00 HERMES INTERNATIONAL Consumer Products & Services France 0.94 SUEZ ENVIRONNEMENT Utilities France 0.94 BRENNTAG Chemicals Germany 0.93 ENAGAS Energy Spain 0.90 ILIAD Telecommunications France 0.89 DEUTSCHE POST Industrial Goods & Services Germany 0.88 FUCHS PETROLUB PREF Chemicals Germany 0.88 SEB Consumer Products & Services France 0.87 SIGNIFY Construction & Materials Netherlands 0.86 CARL ZEISS MEDITEC Health Care Germany 0.80 SOFINA Financial Services Belgium 0.80 EUROFINS SCIENTIFIC Health Care France 0.80 RATIONAL Industrial Goods & Services Germany 0.80 AALBERTS Industrial Goods & Services Netherlands 0.74 KINGSPAN GRP Construction & Materials Ireland 0.73 GERRESHEIMER Health Care Germany 0.72 GLANBIA Food, Beverage & Tobacco Ireland 0.71 PUBLICIS GRP Media France 0.70 UNITED INTERNET Technology Germany 0.70 L'OREAL Consumer Products & Services France 0.70 KPN Telecommunications Netherlands 0.68 SARTORIUS PREF. Health Care Germany 0.68 BMW Automobiles & Parts Germany 0.68 VISCOFAN Food, Beverage & Tobacco Spain 0.67 SAINT GOBAIN Construction & Materials France 0.67 CORBION Food, Beverage & Tobacco Netherlands 0.66 DAIMLER Automobiles & Parts Germany 0.66 PROSIEBENSAT.1 MEDIA Media Germany 0.65
    [Show full text]
  • FACTSHEET - AS of 28-Sep-2021 Solactive Mittelstand & Midcap Deutschland Index (TRN)
    FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) DESCRIPTION The Index reflects the net total return performance of 70 medium/smaller capitalisation companies incorporated in Germany. Weights are based on free float market capitalisation and are increased if significant holdings in a company can be attributed to currentmgmtor company founders. HISTORICAL PERFORMANCE 350 300 250 200 150 100 50 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Jan-2022 Solactive Mittelstand & MidCap Deutschland Index (TRN) CHARACTERISTICS ISIN / WKN DE000SLA1MN9 / SLA1MN Base Value / Base Date 100 Points / 19.09.2008 Bloomberg / Reuters MTTLSTRN Index / .MTTLSTRN Last Price 342.52 Index Calculator Solactive AG Dividends Included (Performance Index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 19.09.2008 Index Members 70 FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -3.69% 3.12% 7.26% 27.72% 12.73% 242.52% Performance (p.a.) - - - - - 9.91% Volatility (p.a.) 13.05% 12.12% 12.48% 13.60% 12.90% 21.43% High 357.49 357.49 357.49 357.49 357.49 357.49 Low 342.52 329.86 315.93 251.01 305.77 52.12 Sharpe Ratio -2.77 1.14 1.27 2.11 1.40 0.49 Max. Drawdown -4.19% -4.19% -4.19% -9.62% -5.56% -47.88% VaR 95 \ 99 -21.5% \ -35.8% -34.5% \ -64.0% CVaR 95 \ 99 -31.5% \ -46.8% -53.5% \ -89.0% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE
    [Show full text]
  • € [•] [•] Per Cent. Notes Due 2019
    Prospectus dated 27 June 2014 Symrise AG (a stock corporation incorporated under the laws of the Federal Republic of Germany, having its corporate domicile in Holzminden, Federal Republic of Germany) € [•] [•] per cent. Notes due 2019 Issue Price: [•] per cent. Symrise AG (the "Issuer" or "Symrise AG") will issue on 10 July 2014 (the "Issue Date") € [•] [•] per cent. Notes due 2019 (the "Notes"). The Notes will be redeemed at par on 10 July 2019. The Notes will bear interest from and including 10 July 2014 to, but excluding, 10 July 2019 at a rate of [•] per cent. per annum, payable annually in arrear on 10 July in each year, commencing on 10 July 2015. This prospectus (the "Prospectus") constitutes a prospectus within the meaning of Article 5.3 of the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended (the "Prospectus Directive"). This Prospectus will be published in electronic form together with all documents incorporated by reference on the website of the Luxembourg Stock Exchange (www.bourse.lu). This Prospectus has been approved by the Commission de Surveillance du Sector Financier of the Grand Duchy of Luxembourg (the "CSSF") in its capacity as competent authority under the Luxembourg law relating to prospectuses (Loi relative aux prospectus pour valeurs mobilières – the "Prospectus Law"), as amended, which implements the Prospectus Directive into Luxembourg law. The Issuer has requested the CSSF to provide the competent authority in the Federal Republic of Germany ("Germany"), the Republic of Austria ("Austria") and The Netherlands with a certificate of approval attesting that the Prospectus has been drawn up in accordance with the Prospectus Law (the "Notification").
    [Show full text]